KORU Medical To Seek FDA Clearance For FreedomEDGE Infusion System In Q4 2025/Q1 2026

KORU Medical said it will file a 510(k) with the FDA in Q4 2025 or Q1 2026 seeking clearance to use its FreedomEDGE Syringe Infusion System with a commercial oncology drug; the device supports large-volume subcutaneous delivery (5–50+ mL) and has an established global footprint (15+ years, >45,000 patients, ~2 million infusions annually across 30+ countries). Results from a nine-hospital multicentre study in Denmark—due to be presented at the ESID/EHA/SIOPE symposium in November 2025—reported high nurse and patient satisfaction and a 97% recommendation rate, with KORU highlighting workflow efficiency and hands‑free scalability. KRMD shares have traded in a $4.32–$4.57 range over the past year and closed at $4.49, up 3.94%, and regulatory clearance combined with positive clinical data would materially support broader oncology adoption and commercial upside while timing and FDA outcome remain determinative.

Analysis

KORU Medical announced plans to submit a 510(k) to the FDA in Q4 2025 or Q1 2026 seeking clearance of its FreedomEDGE Syringe Infusion System for use with a commercialized oncology drug; the system supports large-volume subcutaneous delivery from 5 mL to 50 mL+ and has an established footprint of 15+ years, over 45,000 patients and roughly 2 million infusions annually across 30+ countries. The company will present multicentre data from nine hospitals in Denmark at the ESID/EHA/SIOPE symposium (Nov 18–20, 2025) showing high nurse and patient satisfaction and a 97% recommendation rate in a nursing-preference survey comparing FreedomEDGE to manual push for short-duration subcutaneous infusions. Management frames the device as a scalable, hands‑free alternative that improves workflow efficiency while maintaining patient comfort, which, if corroborated by full study results and FDA clearance, could support adoption in oncology and immunology infusion settings. Market reaction to date is muted — KRMD has traded in a tight $4.32–$4.57 range over the past year and closed at $4.49 (up 3.94%) — highlighting that the primary near-term catalysts are regulatory timing, presentation data details and subsequent commercialization or partnership announcements, while the 510(k) outcome remains a binary risk.

Key Decisions for Investors

• Consider initiating or adding a modest, size‑limited position ahead of the 510(k) filing and the November 2025 data presentation to capture upside from positive regulatory or clinical news, but keep exposure small given binary FDA risk
• Monitor near-term catalysts closely: official 510(k) submission date, FDA feedback/clearance, full multicentre study data release at ESID/EHA/SIOPE (details beyond satisfaction metrics), and any announced partnerships with oncology drug manufacturers
• If already long, consider hedging downside (options or position size reduction) until post‑clearance commercial agreements or clear positive regulatory feedback materialize, and be prepared to trim on any mixed or negative clinical/regulatory updates